Dexmedetomidine for ADHD
Dexmedetomidine is a potent selective α2-adrenoreceptor agonist.
The binding of dexmedetomidine to α2 receptors is 1620 times stronger than to α1 receptors. For comparison: clonidine 220:1.
The affinity for α2 receptors for dexmedetomidine is higher than that for clonidine.
α2-agonists (such as clonidine and guanfacine) are used as 3rd choice ADHD medications.
mediate α2 receptors:
Inhibition of presynaptic noradrenaline release
- Central induction of sedation via the nucleus coeruleus
- Central moderation of pain perception via the dorsal posterior horn
Inhibition of insulin secretion from pancreatic beta cells
All 3 subtypes of α2 receptors inhibit adenylyl cyclase. This reduces cyclic adenosine monophosphate and causes hyperpolarization of noradrenergic neurons in the medial dorsal pons, particularly in the locus coeruleus. When cyclic adenosine monophosphate is inhibited, potassium efflux through calcium-activated channels prevents calcium ions from entering the nerve terminal, which suppresses neuronal firing. This suppression inhibits the release of noradrenaline and decreases the activity of ascending noradrenergic signaling pathways, leading to hypnosis and sedation. This negative feedback loop can further reduce heart rate, blood pressure and sympathetic stress response.
Dexmedetomidine is widely used for sedation and anesthesia in clinical perioperative applications.
Dexmedetomidine activates dopaminergic neurons in the VTA.
Intravenous administration of dexmedetomidine below the usual sedative dose (and without sedative effect) reduced hyperactivity and improved spatial working memory in SHR, a model animal for ADHD.
The use of dexmedetomidine in people with ADHD is not yet known.
Diese Seite wurde am 16.01.2024 zuletzt aktualisiert.